What’s being cut at NIH

A look at the government’s far-reaching rollback in research grants so far.

By Meagan Parrish • April 25, 2025

Flagship’s latest venture reflects more than 25 years of leaping into the unknown

A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

By Michael Gibney • April 24, 2025

Explore the Trendline➔

Tech for Clinical Trials

Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

By PharmaVoice staff

How a scrapped Pfizer drug became a winner for SpringWorks

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

By Alexandra Pecci • April 21, 2025

A big moment is coming for psychedelics

Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

By Meagan Parrish • April 18, 2025

Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments. 

By Alexandra Pecci • April 16, 2025

‘Chaos’ in the biotech market has dampened hopes of a rebound. What does that mean for dealmaking and IPOs?

The biotech market is taking a beating amid Trump’s turbulent economic policies.

By Amy Baxter • April 15, 2025

US risks losing biotech edge to China, report warns

“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.

By Ned Pagliarulo • April 9, 2025

Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.

Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.

By Michael Gibney • April 8, 2025

A birth control pill for men makes moves in the clinic

So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?

By Kelly Bilodeau • April 7, 2025

The year’s biggest biotech haul shows investors are still chasing the AI dream

Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.

By Meagan Parrish • April 4, 2025

Industry leaders react to HHS being ‘reduced to a shell’

What healthcare watchdogs have said about the far-reaching job cuts this week.

By Meagan Parrish and Amy Baxter • April 3, 2025

Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’

Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.

By Michael Gibney • April 1, 2025

With government health info in limbo, drugmakers lose credible sources

The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

By Alexandra Pecci • April 1, 2025

A recent gene therapy death shines a light on AAV safety

This technology brings both benefits and drawbacks for the field, which is also testing alternatives.

By Kelly Bilodeau • March 31, 2025

How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

By Michael Gibney • March 27, 2025

Biogen plots new global headquarters in Kendall Square

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

By Jacob Bell • March 25, 2025

Biotechs emerging from stealth take aim at pharma’s prime targets

The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.

By Kelly Bilodeau • March 24, 2025

Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

By Michael Gibney • March 20, 2025

The key factors shaping China’s biopharma boom

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

By Alexandra Pecci • March 19, 2025

How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

By Michael Gibney • March 18, 2025

Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

By Kelly Bilodeau • March 17, 2025

Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

By Amy Baxter • March 17, 2025

IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

By Amy Baxter • March 12, 2025

The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

By Amy Baxter • March 11, 2025

What’s driving pharma’s layoffs in 2025

Familiar foes in the industry have claimed a slew of jobs in recent months.

By Meagan Parrish • March 10, 2025